Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBT (2021 - 2025)

Historic EBT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $27.2 million.

  • Kiniksa Pharmaceuticals International's EBT rose 47712.82% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 15330.91%. This contributed to the annual value of -$36.2 million for FY2024, which is 6033.05% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its EBT stood at $27.2 million for Q3 2025, which was up 47712.82% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBT ranged from a high of $90.9 million in Q4 2022 and a low of -$72.0 million during Q4 2023
  • Moreover, its 5-year median value for EBT was -$9.4 million (2023), whereas its average is -$6.9 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 17923.51% in 2023, then surged by 89292.53% in 2025.
  • Kiniksa Pharmaceuticals International's EBT (Quarter) stood at -$43.8 million in 2021, then surged by 307.56% to $90.9 million in 2022, then tumbled by 179.24% to -$72.0 million in 2023, then soared by 76.43% to -$17.0 million in 2024, then skyrocketed by 259.94% to $27.2 million in 2025.
  • Its EBT stands at $27.2 million for Q3 2025, versus $22.9 million for Q2 2025 and $15.6 million for Q1 2025.